Gulin-Sarfraz, T.; Jonasson, S.; Wigenstam, E.; von Haartman, E.; Bucht, A.; Rosenholm, J.M.
Feasibility Study of Mesoporous Silica Particles for Pulmonary Drug Delivery: Therapeutic Treatment with Dexamethasone in a Mouse Model of Airway Inflammation. Pharmaceutics 2019, 11, 149.
https://doi.org/10.3390/pharmaceutics11040149
AMA Style
Gulin-Sarfraz T, Jonasson S, Wigenstam E, von Haartman E, Bucht A, Rosenholm JM.
Feasibility Study of Mesoporous Silica Particles for Pulmonary Drug Delivery: Therapeutic Treatment with Dexamethasone in a Mouse Model of Airway Inflammation. Pharmaceutics. 2019; 11(4):149.
https://doi.org/10.3390/pharmaceutics11040149
Chicago/Turabian Style
Gulin-Sarfraz, Tina, Sofia Jonasson, Elisabeth Wigenstam, Eva von Haartman, Anders Bucht, and Jessica M. Rosenholm.
2019. "Feasibility Study of Mesoporous Silica Particles for Pulmonary Drug Delivery: Therapeutic Treatment with Dexamethasone in a Mouse Model of Airway Inflammation" Pharmaceutics 11, no. 4: 149.
https://doi.org/10.3390/pharmaceutics11040149
APA Style
Gulin-Sarfraz, T., Jonasson, S., Wigenstam, E., von Haartman, E., Bucht, A., & Rosenholm, J. M.
(2019). Feasibility Study of Mesoporous Silica Particles for Pulmonary Drug Delivery: Therapeutic Treatment with Dexamethasone in a Mouse Model of Airway Inflammation. Pharmaceutics, 11(4), 149.
https://doi.org/10.3390/pharmaceutics11040149